REFERENCES
- Tzamaloukas AH, Avasthi PS. Temporal profile of serum potassium concentration in nondiabetic and diabetic outpatients on chronic dialysis. Am J Nephrol. 1897;7:101–109.
- Morduchowicz G, Winkler J, Drazne E, Van Dyk DJ, Wittenberg C, Zabludowski JR, Shohat J, Rosendfeld JB, Boner G. Causes of death in patients with end-stage renal disease treated by dialysis in a center in Israel. Isr J Med Sci. 1992;28:776–779.
- Shibata M, Kishi T, Iwata H. Clinical study of complications in dialyzed diabetics. Tohoku J Exp Med. 1983;141:417–425.
- Knoll GA, Sahgal A, Nair RC, Graham J, van Walraven C, Burns KD. Renin-angiotensin system blockade and the risk of hyperkalemia in chronic hemodialysis patients. Am J Med. 2002;112:110–114.
- Han SW, Won YW, Yi JH, Kim HJ. No impact of hyperkalemia with rennin-angiotensin system blockades in maintenance hemodialysis patients. Nephrol Dial Transplant. 2007;22(4):1150–1155.
- Junaid A, Lawrence SW. Hyperkalemia in dialysis patients. Seminars in Dialysis. 2001;14(5):348–356.
- Allon M. Treatment and prevention of hyperkalemia in end-stage renal disease. Kidney Int. 1993;43:1197–1209.
- Sugarman A, Brown RS. The role of aldosterone in potassium tolerance: Studies in anephric patients. Kidney Int. 988(34):397–403.